$Novo Nordisk AS(NVO.US)

On Monday, Wegovy oral weight-loss drug was approved by the FDA and is expected to be launched in the U.S. in January next year. The product is an oral tablet suitable for people aged 12 and above, providing a new option for users who are afraid of injections, which is expected to expand the potential user base. With a first-mover advantage in the time window, this will help Novo Nordisk capture the weight-loss drug market share and secure a more favorable position in future competition.

From the perspective of stock performance, the short-term target is around 60; in the medium to long term, as the oral weight-loss drug gradually gains traction and the market space continues to expand, the stock price may challenge and even break previous highs.